Zolgensma Global Managed Access Program (gMAP)
Novartis
ClosedUnder review·Mar 14, 2026
The Zolgensma® Global Managed Access Program (gMAP) was created in 2020 to provide a pathway for patients to access the one-time gene therapy Zolgensma® (onasemnogene abeparvovec) globally. Its purpose is to broaden access to the medicine. The program description does not explicitly mention coverage for travel expenses.
Apply
Application goes directly to Novartis. RxCopays does not receive compensation.
Go to application →Rare-disease support beyond financial help
This grant covers a rare condition. For specialists, clinical trials, and patient communities, our sister site UniteRare.org has in-depth pages: